We are international
Donate
publications TEXT SIZE   
the understanding series    back

Eastern Cooperative Oncology Group Clinical Trial:E1A05
Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®) & Lenalidomide (Revlimid®) - Dexamethasone (VRD) versus Bortezomib (Velcade®:) - Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen
11.20.07
This is a randomized study using Lenolidamide (also called Revlimid) in combination with a steroid, dexamethasone (also called Decadron), with and without Bortezomib (also called Velcade.) Patients are eligible to participate if they have completed a dexamethasone-based treatment as their first treatment for myeloma and are not going on to a stem cell transplant at this time.

Patients will be randomly assigned to one of two groups:

* Group 1 will receive Lenalidomide with dexamethasone
* Group 2 will receive Lenalidomide with dexamethasone and Bortezomib

All patients will participate in a Quality of Life Survey during treatment and after treatment. All patients will be followed for up to seven years to assess the long-term effects of the study treatments.

  • List of Institutions participating in this trial.


  •  related articles